Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q73850407)
Watch
English
Pharmacodynamic aspects of peptide administration biological response modifiers
scientific article published on 01 September 1998
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
title
Pharmacodynamic aspects of peptide administration biological response modifiers
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
main subject
pharmacodynamics
1 reference
based on heuristic
inferred from title
author name string
Talmadge JE
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
publication date
1 September 1998
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
published in
Advanced Drug Delivery Reviews
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
volume
33
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
issue
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
page(s)
241-252
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
cites work
Mutagenesis of human granulocyte colony stimulating factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Disulfide and secondary structures of recombinant human granulocyte colony stimulating factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
FDA okays surrogate markers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alpha interferon for induction of remission in hairy-cell leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adjuvant therapy for melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytokine therapy for hematological malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The determination of an immunologically active dose of interferon-gamma in patients with melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic/Pharmacodynamic Analysis of Neutrophil Proliferation Induced by Recombinant Granulocyte Colony-Stimulating Factor (rhG-CSF): Comparison between Intravenous and Subcutaneous Administration
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Approval times for supplemental indications for recombinant proteins
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900032-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0169-409X(98)00032-5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
PubMed publication ID
10837664
1 reference
stated in
Europe PubMed Central
PubMed publication ID
10837664
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837664%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
